Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cjca.2018.10.013 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ranolazine in chronic total occlusion percutaneous coronary intervention.
J Invasive Cardiol
October 2024
Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, Abbott Northwestern Hospital, Minneapolis, Minnesota, USA. Email:
Ranolazine is an anti-anginal medication given to patients with chronic angina and persistent symptoms despite medical therapy. We examined 11 491 chronic total occlusion (CTO) percutaneous coronary interventions (PCI) that were performed at 41 US and non-US centers between 2012 and 2023 in the PROGRESS-CTO Registry. Patients on ranolazine at baseline had more comorbidities, more complex lesions, lower procedural and technical success (based on univariable but not multivariable analysis), and higher incidence of major adverse cardiac events (MACE) (on both univariable and multivariable analysis).
View Article and Find Full Text PDFAchieving optimal adherence to medical therapy by telehealth: Findings from the ORBITA medication adherence sub-study.
Pharmacol Res Perspect
February 2021
Department of Chemical Pathology and Metabolic Diseases, University Hospitals of Leicester, Leicester, UK.
Introduction: The ORBITA trial of percutaneous coronary intervention (PCI) versus a placebo procedure for patients with stable angina was conducted across six sites in the United Kingdom via home monitoring and telephone consultations. Patients underwent detailed assessment of medication adherence which allowed us to measure the efficacy of the implementation of the optimization protocol and interpretation of the main trial endpoints.
Methods: Prescribing data were collected throughout the trial.
A critical appraisal of the pharmacological management of stable angina.
Hellenic J Cardiol
August 2021
Department of Cardiology, Larissa University Hospital, University of Thessaly Medical School, Larissa, Greece.
The once dominant plaque-centric model of the pathophysiology and management of coronary artery disease (CAD) has long been questioned by a bulk of experimental and clinical evidence suggesting, among others, that coronary artery obstruction is not synonymous with myocardial ischaemia, ischaemia may occur in the absence of obstructive lesions and may persist after successful coronary revascularization, while elective revascularization provides little or no prognostic benefit. As a result, a paradigm shift has been suggested taking into consideration the multifactorial aspect of CAD such as microvascular disease and the consequences of ischemia at the level of cardiomyocyte. In this paper, we propose an alternative approach to the medical management of patients with chronic CAD and stable angina, based on the properties of the drugs currently available in the anti-ischemic armamentarium in relation to the pathophysiology of myocardial ischemia.
View Article and Find Full Text PDFThe Role of Ranolazine for the Treatment of Residual Angina beyond the Percutaneous Coronary Revascularization.
J Clin Med
July 2020
Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Umberto I Hospital, Sapienza University of Rome, 00161 Rome, Italy.
Introduction: Despite a successful percutaneous coronary intervention (PCI), several studies reported that the recurrence of angina after revascularization, even complete, is a particularly frequent occurrence in the first year after PCI.
Methods: The aim was to evaluate the efficacy of treatment with ranolazine in addition to conventional anti-ischemic therapy in patients who underwent coronary angiography for persistent/recurrent angina after PCI and residual ischemia only due to small branches not suitable for further revascularization. Forty-nine consecutive patients were included in our registry, adding the ranolazine (375 mg b.
Specific Therapy Based on the Genotype in a Malignant Form of Long QT3, Carrying the V411M Mutation.
Int Heart J
July 2019
Division of Pacing and Electrophysiology, Rambam Health Care Campus, Technion Medical School.
Congenital long QT syndrome (LQTS) is a cardiac channelopathy that leads to the prolongation of the QT interval. This prolongation can lead to ventricular tachyarrhythmia, syncope, and sudden cardiac death. There are various types of LQTS.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!